Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Better Reimbursement, More Incentives Needed For Peds Device Development, Stakeholders Tell FDA

Executive Summary

At a recent pediatric medical devices workshop at US FDA headquarters, the focus turned less to regulatory burdens and more to lacking reimbursement and financial incentives as barriers to bringing child-focused products to market.

You may also be interested in...



FDA To Hold Postponed 3-Day Pediatric Device Workshop In February

The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.

Despite COVID-19, Expert Group Moves Ahead With Public Meeting On Pediatric Device Development

While the US FDA has been developing a framework over the past few years to address the lack of pediatric devices on the market, the agency awarded a grant to the multi-stakeholder group C-Path to continue that work at the same time that the coronavirus pandemic started. Despite the hurdles, C-Path says it is still doing its work and plans to convene a public meeting on the issue in September.

Pre-Certs, Test Groups And More: US FDA Outlines Possible New Dx Paradigm

The agency has responded to a draft diagnostics reform bill in Congress with proposed reforms that diverge some ways from the proposed legislation, but stick with the underlying goal of completely remaking how lab tests, including test kits and lab-developed tests, are regulated. The agency has put forward a proposal to establish a pre-certification process for test developers, divide most tests into high- or low-risk categories (but exempt many from pre-market review) and remove the concept of substantial equivalence.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT123163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel